The efficacy and safety of targeted agents approved for advanced non-small cell lung cancer in China: a cross-sectional analysis
Background: Lung cancer, as the disease with the highest mortality and incidence rate in China, has emerged as one of the most heavily burdened diseases. Recently, China has approved several targeted cancer agents for advanced first-line non-small cell lung cancer (NSCLC), including small molecule d...
Saved in:
| Main Authors: | Xingxian Luo, Xin Du, Xufeng Lv, Lizong Li, Lin Huang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | The Lancet Regional Health. Western Pacific |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666606524004383 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Progress and challenges of confirmatory trials for cancer drugs granted conditional approval in China
by: Xingxian Luo, et al.
Published: (2024-11-01) -
Real-world Study of the Safety and Efficacy of Pembrolizumab in the Treatment
of Advanced Non-small Cell Lung Cancer
by: Ning WAN, et al.
Published: (2024-10-01) -
Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases
by: Hai-Zhen Yi, et al.
Published: (2025-07-01) -
Safety and efficacy of rechallenge with immune checkpoint inhibitors and anlotinib in advanced non-small cell lung cancer without targetable driver mutations: a retrospective analysis
by: Xinrong Chen, et al.
Published: (2025-05-01) -
Efficacy and Safety of Perioperative Immunotherapy for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
by: Zhijuan Du, et al.
Published: (2025-03-01)